Over the latest trailing 12-month period, total return cagr is +12.01%. The comparable SPY value is +16.94%. Year-to-date total return is +11.29%. Total return includes price appreciation and reinvested dividends.
Over the past 12 months, Total Return CAGR is 12.01%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Contineum Therapeutics, Inc. (CTNM)
Total Return growth vs the same calendar quarter one year earlier, last 7 comparable quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $82.60.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:36:27.191Z. Historical observations retain their original dates. Historical series through 2024-08-14.
Unrounded diluted TTM EPS / FMP quote price × 100 Quote observation: 2026-10-06T16:36:27.191Z. Historical observations retain their original dates. Historical series through 2024-08-14.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | +11.29% |
| 2025 | -21.98% |
| Period | Period End | QoQ Return | YoY Return |
|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | -5.2% | +11.3% |
| Q3 2026 | 2026-09-30 | -18.1% | +14.2% |
| Q2 2026 | 2026-06-30 | +25.5% | +312.8% |
| Q1 2026 | 2026-03-31 | +14.3% | +87.1% |
| Q4 2025 | 2025-12-31 | -2.7% | -22.0% |
| Q3 2025 | 2025-09-30 | +196.0% | -38.6% |
| Q2 2025 | 2025-06-30 | -43.1% | -77.5% |
| Q1 2025 | 2025-03-31 |
| -52.4% |
| N/A |
| Q4 2024 | 2024-12-31 | -23.5% | N/A |
| Q3 2024 | 2024-09-30 | +8.7% | N/A |
| Q2 2024 | 2024-06-28 | N/A | N/A |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
